PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
A new study suggests that doing a moderate amount of strength training every week may help people live longer, especially when it is combined with regular aerobic exercise such as walking, running, cycling, or swimming. Researchers analyzed data from three large long-term health studies involving...
A group of nutrition, metabolism, and eating behavior experts from across Europe has questioned the common belief that all ultra-processed foods (UPFs) are harmful to health. In a Perspective article published in the journal Science, researchers reviewed five clinical trials conducted in the US, UK,...
Screens are now part of every childhood, but research continues to show that too much screen time can slow communication, attention, and daily living skills. A 2023 JAMA Pediatrics study found toddlers with more than an hour of daily screen exposures at age two struggled by age four. Outdoor play—even simple park time—helped offset these risks, especially for social skills.
InnoCare Pharma Limited (INCPF), a biopharmaceutical company, on Friday announced promising Phase 2b results for Orelabrutinib in treating systemic lupus erythematosus (SLE). The data was presented at the 2026 Congress of the European Alliance of Associations for Rheumatology (EULAR). Systemic lupus...